IL-23, rather than IL-17, is crucial for the development of ovalbumin-induced allergic rhinitis

•Both IL-23 and IL-17 were produced mainly by nasal ECs during OVA-induced AR.•IL-23, but not IL-17, was crucial for the development of OVA-induced AR.•IL-23 neutralization may be a potential approach for treatment of OVA-induced AR. Interleukin-23 (IL-23) and IL-17 are involved in the pathogenesis...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Molecular immunology 2015-10, Vol.67 (2), p.436-443
Hauptverfasser: Guo, Chaobin, Chen, Guie, Ge, Ruifeng
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•Both IL-23 and IL-17 were produced mainly by nasal ECs during OVA-induced AR.•IL-23, but not IL-17, was crucial for the development of OVA-induced AR.•IL-23 neutralization may be a potential approach for treatment of OVA-induced AR. Interleukin-23 (IL-23) and IL-17 are involved in the pathogenesis of allergic rhinitis (AR). However, the roles of IL-23 and IL-17 in ovalbumin (OVA)-induced AR remain unclear. Therefore in this study we aim to investigate the precise roles of IL-23 and IL-17 in a mouse model of OVA-induced AR. We found that during OVA-induced AR, eosinophil and goblet cells in the nose were significantly decreased in IL-23-deficient, but not in IL-17-deficient mice. However, there was no difference in the serum IgE and IgG1 levels between IL-23-deficient or IL-17-deficient and wild-type mice. Moreover, IL-4 levels in lymph node cell culture supernatants were significantly decreased in IL-23-deficient, but not IL-17-deficient, compared with wild-type mice. Furthermore, OVA-induced AR developed similarly in wild-type mice transferred with either IL-23-deficient BM cells or wild-type BM cells. These findings suggest that IL-23, but not IL-17 is crucial for the development of OVA-induced AR, and IL-23 neutralization may be a potential approach for treatment of OVA-induced AR in humans.
ISSN:0161-5890
1872-9142
DOI:10.1016/j.molimm.2015.07.009